A214260 Stock Overview
Raphas Co., Ltd. provides skin-based drug delivery systems in South Korea, Japan, and China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Raphas Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,520.00 |
| 52 Week High | ₩31,450.00 |
| 52 Week Low | ₩13,100.00 |
| Beta | 1.66 |
| 1 Month Change | -22.03% |
| 3 Month Change | -23.14% |
| 1 Year Change | -30.27% |
| 3 Year Change | -64.28% |
| 5 Year Change | n/a |
| Change since IPO | -25.10% |
Recent News & Updates
Shareholder Returns
| A214260 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | -1.7% | -0.7% | -0.4% |
| 1Y | -30.3% | -2.9% | 4.5% |
Return vs Industry: A214260 underperformed the KR Personal Products industry which returned -1.7% over the past year.
Return vs Market: A214260 underperformed the KR Market which returned 7.1% over the past year.
Price Volatility
| A214260 volatility | |
|---|---|
| A214260 Average Weekly Movement | 5.3% |
| Personal Products Industry Average Movement | 5.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A214260's share price has been volatile over the past 3 months.
Volatility Over Time: A214260's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 92 | Dohyeon Jeong | www.raphas.co.kr |
Raphas Co., Ltd. provides skin-based drug delivery systems in South Korea, Japan, and China. The company offers cosmetics under the Acropass brand. It also provides original design manufacturer services in producing cosmetics for various needs, such as wrinkle reduction, freckle, and acne treatment; and medical contract manufacturing services.
Raphas Co., Ltd. Fundamentals Summary
| A214260 fundamental statistics | |
|---|---|
| Market cap | ₩115.92b |
| Earnings (TTM) | -₩8.80b |
| Revenue (TTM) | ₩27.94b |
4.1x
P/S Ratio-13.2x
P/E RatioIs A214260 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A214260 income statement (TTM) | |
|---|---|
| Revenue | ₩27.94b |
| Cost of Revenue | ₩15.39b |
| Gross Profit | ₩12.55b |
| Other Expenses | ₩21.35b |
| Earnings | -₩8.80b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.03k |
| Gross Margin | 44.91% |
| Net Profit Margin | -31.52% |
| Debt/Equity Ratio | 135.0% |
How did A214260 perform over the long term?
See historical performance and comparison